CareDx (CDNA)
(Delayed Data from NSDQ)
$29.63 USD
-0.25 (-0.84%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $29.64 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum C VGM
Brokerage Reports
0 items in cart
CareDx, Inc. [CDNA]
Reports for Purchase
Showing records 21 - 40 ( 83 total )
Company: CareDx, Inc.
Industry: Medical Services
CDNA Wins False Advertising Case; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Robust Top-Line Growth in 2021; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Preliminary Full Year 2021 Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
CLIA Validation of AlloMap Kidney Completed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
LungCare Registry Study Commences Patient Enrollment; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
AlloCare Health App Study Commences Patient Enrollment; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Top-Line Growth Solid in 3Q21; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
AlloSure Test Launched for Lung Transplant Patients; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
KidneyCare Validation Study Published; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Company: CareDx, Inc.
Industry: Medical Services
Robust 2Q21 Top-Line Growth; Full-Year Guidance Raised; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
KOAR Study Reports Positive Preliminary Data; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Post-Transplant LiverCare Study Starts Enrollment; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Strategic Investment in Transplantable Organs; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
1Q21 Financial Performance Lifts 2021 Revenue Guidance; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Robust Top-Line Growth in 2020; Downgrading to Neutral Due to Valuation
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Robust Top-Line Growth in 3Q20; Reiterate Buy; Raising PT to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
Preliminary 3Q20 Revenue Reported; Reiterate Buy; Raising PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
AlloSure Lung Clinical Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CareDx, Inc.
Industry: Medical Services
AlloSure Heart Secures Medicare Coverage; Reiterate Buy; Raising PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y